Professor of Medicine
Cedars-Sinai Medical Center
Agoura Hills, California, United States
Dr. Vic Tapson, MD, FCCP, FRCP, spent two decades at Duke University and co-founded the Lung Transplant, CTEPH, and Pulmonary Vascular Disease Centers. He moved to Cedars-Sinai in Los Angeles in 2014 focusing on pulmonary embolism (PE) and pulmonary hypertension.
He chaired the ATS guidelines for the diagnosis of VTE (1999) and has served on the ACCP VTE and international VTE guidelines. He was a member of the World Pulmonary Hypertension Guidelines Committee since 2003 (most recently the CTEPH section). He served as an author for several PE sections of UpToDate for 25 years, and served as the first elected President of the U.S. PERT Consortium.
Dr. Tapson has published invited review articles on PE in the New England Journal of Medicine, and other journals. He was elected to the Royal College of Physicians in 2010. During the first 18 months of the pandemic, he served 24/7 as the only frontline PERT faculty at Cedars-Sinai. He has served as world-wide principal investigator (PI) or co-PI for many VTE registries and trials including DVT-FREE, IMPROVE, NABOR, ENDORSE, the TAFIa clinical trial, the BiO2 IVCF study, and the FLARE catheter embolectomy study, and designed and conceived and ran the OPTALYSE PE trial. He has served on the steering committee for a number of other PE trials including PIOPED II, PIOPED III, EXTRACT, aand RESCUE. He joined Inari Medical (now part of Stryker) in October 2021 as VP of Medical Affairs and is involved with clinical trial design, research and medical education. He continues as Professor of Medicine at Cedars-Sinai in Los Angeles focusing on PE Dr. Tapson has authored more than 330 peer-reviewed manuscripts. He enjoys patient care, teaching and cliical research, and has lectured in more than 40 countries.
The Evidence for PE Intervention: Is There a Mortality Benefit and Does it Matter?
Tuesday, March 3, 2026
9:00 AM - 9:08 AM MST